-

Blackstone Life Sciences Announces $750 Million R&D Funding Agreement

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone announced today that funds managed by Blackstone Life Sciences (“Blackstone”) will provide $750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (“Ollin”).

“We are pleased to expand our relationship with Johnson & Johnson by supporting the Phase 3 development of OLN324,” said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. “Our financing demonstrates our ability to provide capital at scale to help leading pharmaceutical companies pursue strategic opportunities and advance innovative medicines that have the potential to improve patients’ lives.”

“OLN324 has demonstrated encouraging early clinical results and represents a differentiated approach to treating serious retinal vascular diseases that could deliver meaningful benefits for patients,” said Kiran Reddy, Senior Managing Director at Blackstone Life Sciences. “We are excited to work with Johnson & Johnson to help advance this promising new treatment option to patients.”

The agreement is subject to the acquisition of Ollin by Johnson & Johnson, which is subject to customary closing conditions including receipt of regulatory approvals. As part of its investment, Blackstone is entitled to certain regulatory and sales milestone payments as well as single digit royalties.

About Blackstone Life Sciences

Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $18 billion in assets under management.

Contacts

David Vitek
(212) 583-5291
David.Vitek@Blackstone.com

Blackstone Life Sciences

NYSE:BX

Release Versions

Contacts

David Vitek
(212) 583-5291
David.Vitek@Blackstone.com

More News From Blackstone Life Sciences

Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infarc...

Blackstone Completes Senior Notes Offering

NEW YORK--(BUSINESS WIRE)--Blackstone (NYSE: BX) announced the completion of the previously announced offering of $600 million of 5.650% senior notes due 2031 and $500 million of 5.900% senior notes due 2033 of Blackstone Reg Finance Co. L.L.C., its indirect subsidiary. The notes are fully and unconditionally guaranteed by Blackstone Inc. and its indirect subsidiaries, Blackstone Holdings I L.P., Blackstone Holdings AI L.P., Blackstone Holdings II L.P., Blackstone Holdings III L.P. and Blacksto...

Blackstone and Leading Canadian Institutional Investors Announce $3.1B Investment in Mitsubishi Corporation’s Interest in LNG Canada

NEW YORK--(BUSINESS WIRE)--Blackstone today announced that funds managed by Blackstone Credit & Insurance, in partnership with leading Canadian institutional investors, have agreed to invest $3.1 billion to acquire a 49.9% non-controlling interest in a Mitsubishi Corporation (“MC”) subsidiary that holds MC’s interest in the LNG Canada liquefaction business. The Blackstone-led investor group includes Canada Pension Plan Investment Board (CPP Investments), through wholly owned subsidiaries of...
Back to Newsroom